A study discovered that MET in MET-amplified EGFR-TKI-resistant cells inhibits STING-induced tumor immunogenicity by increasing CD73 expression, serving as a novel immune checkpoint and potential therapeutic target to enhance extracellular adenosine (eADO) production. Here, EGFR is linked to neoplasm.